Skip to main content
CELC
NASDAQ Industrial Applications And Services

Celcuity Q2 Loss Widens to $78.9M on Launch Costs; $50M Pfizer Milestone Accrued

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$87.01
Mkt Cap
$4.223B
52W Low
$44.42
52W High
$151.02
52W Position info
96% above low
Off High info
42% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CELC sits 96% above its 52-week low of $44.42.

Summary

Celcuity reported a wider Q2 net loss of $78.9 million on commercialization spending, recognized a $50 million Pfizer milestone, and disclosed $754 million in cash runway into 2029.


Key Events · Earnings and Guidance · CELC

  • Q2 Net Loss Widens to $78.9M

    Net loss for Q2 2026 was $78.9 million, up from $45.3 million in Q2 2025, driven by a $27.4 million increase in selling, general and administrative expenses to $35.0 million as the company scaled commercial operations for REVTORPYK.

  • $50M Pfizer Milestone Accrued

    Following FDA approval on July 14, 2026, Celcuity recognized a $50.0 million accrued license milestone and corresponding intangible asset as of June 30, 2026, payable to Pfizer within 60 days.

  • $11.5M Debt Extinguishment Loss

    The company recorded an $11.5 million non-cash loss on debt extinguishment after using $137.4 million of convertible note proceeds to voluntarily prepay its Amended & Restated Loan Agreement on June 8, 2026.

  • Cash Runway into 2029

    Cash, cash equivalents and short-term investments totaled $754.0 million as of June 30, 2026. Management believes this is sufficient to fund planned operations at least into 2029.


Analysis · CELC · Industrial Applications And Services

Celcuity's second-quarter loss widened to $78.9 million from $45.3 million a year earlier, driven by a $27.4 million surge in selling, general and administrative expenses as the company built out its commercial infrastructure for REVTORPYK. The quarter also included an $11.5 million non-cash loss on debt extinguishment from paying off its secured loan. The company recognized a $50 million accrued license milestone to Pfizer following FDA approval, and ended the quarter with $754 million in cash and investments, which management says funds operations into 2029.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CELC was trading at $87.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $44.42 to $151.02. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $56.13 info
Change: -$10.19 (-15%) info
Market Cap: $2.751B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $56.13 info
Change: -$7.91 (-12%) info
Market Cap: $2.751B info
CELC
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $56.13 info
Change: -$7.91 (-12%) info
Market Cap: $2.751B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $56.13 info
Change: -$7.91 (-12%) info
Market Cap: $2.751B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $56.13 info
Change: -$22.87 (-29%) info
Market Cap: $2.751B info